**Core Concept**
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit platelet aggregation by irreversibly blocking the enzyme cyclooxygenase (COX), thereby preventing the formation of thromboxane A2, a potent vasoconstrictor and platelet activator.

**Why the Correct Answer is Right**
The correct answer involves the inhibition of platelet aggregation by blocking the COX enzyme, which is responsible for converting arachidonic acid to prostaglandin H2. This prostaglandin is then converted to thromboxane A2 by the enzyme thromboxane synthase. Thromboxane A2 stimulates platelet activation and aggregation, leading to thrombus formation. By inhibiting COX, aspirin and other NSAIDs prevent the formation of thromboxane A2, thereby inhibiting platelet aggregation.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is not relevant to platelet aggregation inhibition. Instead, it might be related to a different pharmacological action or mechanism.
**Option B:** This option might be related to another mechanism of platelet aggregation inhibition, such as the use of anticoagulant medications like heparin or warfarin. However, it is not the correct answer in this case.
**Option C:** This option is not a correct answer for platelet aggregation inhibition. It might be related to a different pharmacological action or mechanism.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that aspirin's antiplatelet effect is irreversible and lasts for the lifespan of the platelet (approximately 7-10 days). This means that even after aspirin is discontinued, platelets that were exposed to aspirin will continue to be inhibited.

**Correct Answer:** A. Aspirin.